Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
UCB Biopharma S.P.R.L.
Christopher T Ritchlin; Arthur Kavanaugh; Joseph F Merola; Georg Schett; Jose U Scher; Richard B Warren; Alice B Gottlieb; Deepak Assudani; Kathy Bedford-Rice; Jason Coarse; Barbara Ink; Iain B McInnes